Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30191398 | 0.92 | GAA (0.44) | GAABTKCTSKKDM1AMAOB | |
| SCHEMBL18926195 | 0.92 | GAA (0.44) | GAABTKCTSKKDM1AMAOB | |
| SCHEMBL15061530 | 0.89 | GAA (0.47) | GAABTKCTSKKDM1AMAOB | |
| SCHEMBL10238604 | 0.89 | GAA (0.47) | GAABTKCTSKKDM1AMAOB | |
| SCHEMBL16674640 | 0.89 | GAA (0.47) | GAABTKCTSKKDM1AMAOB | |
| SCHEMBL2306830 | 0.88 | KDM1A (0.46) | GAABTKCTSKKDM1AMAOB | |
| SCHEMBL2306821 | 0.88 | KDM1A (0.46) | GAABTKCTSKKDM1AMAOB | |
| SCHEMBL2306823 | 0.88 | KDM1A (0.46) | GAABTKCTSKKDM1AMAOB | |
| SCHEMBL22339495 | 0.88 | GAA (0.54) | GAABTKCTSKKDM1AMAOB | |
| SCHEMBL16202707 | 0.87 | GAA (0.46) | GAABTKCTSKKDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | WELLS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-3825316-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2021-05-26 | — | — | EP | disclosed |
| EP-3489236-B1 | PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-30 | — | — | EP | disclosed |
| EP-3489236-A1 | PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES | Takeda Pharmaceutical Company Limited (JP) | 2019-05-29 | — | — | EP | disclosed |
| EP-2902392-B1 | Fused heteroaromatic pyrrolidinones as syk inhibitors | TAKEDA PHARMACEUTICALS CO (JP) | 2018-10-17 | — | — | EP | disclosed |
| US-20180141951-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | CALITHERA BIOSCIENCES, INC. | 2018-05-24 | — | — | US | disclosed |
| US-20150336964-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-26 | — | — | US | disclosed |
| US-9108970-B2 | Fused heteroaromatic pyrrolidinones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-18 | — | — | US | disclosed |
| EP-2516434-B1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2015-05-27 | — | — | EP | disclosed |
| US-20130245031-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2013-09-19 | — | — | US | disclosed |
| US-8440689-B2 | Fused heteroaromatic pyrrolidinones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-14 | — | — | US | disclosed |
| US-20110152273-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141951-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | GAA 2316/4885BTK 6/4885CTSK 1889/4885 |
| US-20130245031-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | GAA 2316/4885BTK 6/4885CTSK 1889/4885 |
| US-20110152273-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | GAA 2316/4885BTK 6/4885CTSK 1889/4885 |
| US-20150336964-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | GAA 2316/4885BTK 6/4885CTSK 1889/4885 |
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | GAA 2316/4885BTK 6/4885CTSK 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.